{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:10:39Z","timestamp":1788477039852,"version":"build-2803163510"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Lymphomas encompass a heterogeneous group of B- and T-cell malignancies necessitating a complex and precise management. With the aim to define standardized diagnostic and therapeutic pathways across multiple hematology centers in Italy, the \u201cRight Path 4 Lymphomas\u201d project was designed as a multidisciplinary expert platform designed to establish consensus-driven diagnostic and therapeutic pathways.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using a two-phase methodology \u2013 the Nominal Group Technique followed by a Delphi process \u2013 experts systematically evaluated and prioritized key diagnostic and therapeutic topics for five major lymphoma subtypes: classical Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and peripheral T-cell lymphomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The Delphi process achieved a high level of consensus on 264 of 270 statements (97.8%), reinforcing the importance of multidisciplinary collaboration in shaping evidence-based recommendations. Key areas of agreement included histopathologic and molecular diagnostic standards, risk-adapted treatment approaches integrating novel immunotherapies, and structured follow-up strategies. However, areas of debate remained over the clinical utility of minimal residual disease monitoring, optimal sequencing of immunotherapies, and the potential of CAR-T therapy versus bispecific antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This project highlights the need for a structured, consensus-driven approach to lymphoma care that aligns with evolving international guidelines while addressing the distinct regulatory and healthcare landscape in Italy. The findings provide a valuable framework for clinicians and policymakers to optimize lymphoma management, balancing innovation with the allocation of resources and clinical feasibility.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1627175","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:32:43Z","timestamp":1755063163000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic and therapeutic pathways for lymphoma patients: expert consensus through Nominal Group Technique and Delphi methodology"],"prefix":"10.3389","volume":"15","author":[{"given":"Attilio","family":"Guarini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bozzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Ciavarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cimminiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Donatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Fama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza Fernanda","family":"Fesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Fraticelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Martellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Merchionne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna Maria","family":"Miccolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Minoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Pennese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommasina","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Potito Rosario","family":"Scalzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Scattone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetiana","family":"Skrypets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tonialini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Valvano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"B1","article-title":"Lymphoma","volume-title":"StatPearls","author":"Jamil","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejh.13863","article-title":"The diagnosis and management of suspected lymphoma in general practice","volume":"110","author":"Paquin","year":"2023","journal-title":"Eur J Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010005","article-title":"Epidemiology of non-hodgkin's lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"B4","article-title":"Hodgkin Lymphoma","volume-title":"StatPearls","author":"Kaseb","year":"2025"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2023.101449","article-title":"Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults","volume":"36","author":"Temple","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081917","article-title":"Monoclonal antibodies in the treatment of diffuse large B-cell lymphoma: moving beyond rituximab","volume":"14","author":"Papageorgiou","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225397","article-title":"Changing trends in B-cell non-hodgkin lymphoma treatment: the role of novel monoclonal antibodies in clinical practice","volume":"15","author":"Tavarozzi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.11.010","article-title":"The novel therapeutic landscape for relapsed\/refractory diffuse large B cell lymphoma","volume":"22","author":"Nuvvula","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13423","article-title":"Towards precision medicine in lymphoid Malignancies","volume":"292","author":"B\u00fchler","year":"2022","journal-title":"J Intern Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2021.07.015","article-title":"Diagnostic utility of gene fusion panel to detect gene fusions in fresh and formalin-fixed, paraffin-embedded cancer specimens","volume":"23","author":"Haley","year":"2021","journal-title":"J Mol Diagn"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203511","article-title":"Enhancing lymphoma diagnosis, treatment, and follow-up using 18F-FDG PET\/CT imaging: contribution of artificial intelligence and radiomics analysis","volume":"16","author":"Hasanabadi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B15","volume-title":"Group techniques for program planning: a guide to nominal group and Delphi processes","author":"Delbecq","year":"1975"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7001.376","article-title":"Consensus methods for medical and health services research","volume":"311","author":"Jones","year":"1995","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"B18","first-page":"1","volume-title":"The Delphi Method: Techniques and Applications","author":"Linstone","year":"1995"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2070(99)00018-7","article-title":"The Delphi technique as a forecasting tool: issues and analysis","volume":"15","author":"Rowe","year":"1999","journal-title":"Int J Forecast"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-4356(03)00211-7","article-title":"Delphi as a method to establish consensus for diagnostic criteria","volume":"56","author":"Graham","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19422","article-title":"Management of vaccinations in patients with non-Hodgkin lymphoma","volume":"204","author":"Merli","year":"2024","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010061","article-title":"Late cardiological sequelae and long-term monitoring in classical hodgkin lymphoma and diffuse large B-cell lymphoma survivors: A systematic review by the fondazione italiana linfomi","volume":"14","author":"Oliva","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122976","article-title":"Long-term follow-up of classical hodgkin lymphoma and diffuse large B-cell lymphoma survivors: aims and methodological approach for fondazione italiana linfomi systematic reviews","volume":"13","author":"Gerardi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1252433","article-title":"Fertility preservation and monitoring in adult patients diagnosed with lymphoma: consensus-based practical recommendations by the Fondazione Italiana Linfomi & Societ\u00e0 Italiana della Riproduzione Umana","volume":"13","author":"Minoia","year":"2023","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"crossref","unstructured":"Gazzetta Ufficiale n.15 - 20\/01\/2025","DOI":"10.1055\/a-2451-3517"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.blre.2016.09.004","article-title":"High grade B-cell lymphoma with rearrangements of MYC and BCL2 and\/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma","volume":"31","author":"Rosenthal","year":"2017","journal-title":"Blood Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211013987","article-title":"Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications","volume":"12","author":"Papageorgiou","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12672-023-00754-8","article-title":"Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations","volume":"14","author":"Chan","year":"2023","journal-title":"Discov Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the fondazione italiana linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15747","article-title":"Dose-adjusted EPOCH-R is a safe and well tolerated outpatient treatment regimen in double-hit lymphoma","volume":"53","author":"Nelles","year":"2023","journal-title":"Intern Med J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.275958","article-title":"Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"106","author":"Duell","year":"2021","journal-title":"Haematologica"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05196-4","article-title":"MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin\/bendamustine\/rituximab (pola-BR), CAR-T therapies, and lenalidomide\/rituximab (R2) based on real-world data in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"102","author":"Nowakowski","year":"2023","journal-title":"Ann Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283459","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282014","article-title":"Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience","volume":"108","author":"Suleman","year":"2023","journal-title":"Haematologica"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2435-7","article-title":"Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study","volume":"133","author":"Houillier","year":"2017","journal-title":"J Neurooncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01373","article-title":"Omission of radiotherapy in primary mediastinal B-cell lymphoma: IELSG37 trial results","volume":"42","author":"Martelli","year":"2024","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123191","article-title":"Diffuse large B-cell lymphoma in the HIV setting","volume":"15","author":"Huguet","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18763","article-title":"Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies","volume":"201","author":"Atallah-Yunes","year":"2023","journal-title":"Br J Haematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2508","article-title":"Novel acquisitions on biology and management of transformed follicular lymphoma","volume":"36","author":"Minoia","year":"2018","journal-title":"Hematol Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41408-024-01111-w","article-title":"Identification of genetic subtypes in follicular lymphoma","volume":"14","author":"Shelton","year":"2024","journal-title":"Blood Cancer J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2922","article-title":"Prognostic ability of five clinical risk scores in follicular lymphoma: A single-center evaluation","volume":"39","author":"Mozas","year":"2021","journal-title":"Hematol Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27711","article-title":"Total metabolic tumor volume is a strong independent prognostic factor in follicular lymphomas: results from a sub-study of the FOLL12 trial","volume":"100","author":"Durmo","year":"2025","journal-title":"Am J Hematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5281","article-title":"Minimal residual disease assessment in lymphoma: methods and applications","volume":"35","author":"Herrera","year":"2017","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2016.041","article-title":"Limited stage follicular lymphoma: current role of radiation therapy","volume":"8","author":"Filippi","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000160","article-title":"Rituximab with involved field irradiation for early-stage nodal follicular lymphoma: results of the MIR study","volume":"2","author":"Herfarth","year":"2018","journal-title":"Hemasphere"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00034-1","article-title":"Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial","volume":"12","author":"Northend","year":"2025","journal-title":"Lancet Haematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3184","article-title":"Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment na\u00efve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi","volume":"41","author":"Nizzoli","year":"2023","journal-title":"Hematol Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000847280.69256.81","article-title":"P1103: INMIND: a phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed\/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL)","volume":"6","author":"Sehn","year":"2022","journal-title":"Hemasphere"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022352","article-title":"Frontline management of mantle cell lymphoma","volume":"145","author":"Ryan","year":"2025","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17419","article-title":"Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches","volume":"195","author":"Silkenstedt","year":"2021","journal-title":"Br J Haematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11020123","article-title":"18F-FDG PET\/CT cannot substitute endoscopy in the staging of gastrointestinal involvement in mantle cell lymphoma. A retrospective multi-center cohort analysis","volume":"11","author":"Skrypets","year":"2021","journal-title":"J Pers Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16534","article-title":"Clinicopathological and immunohistochemical profile of mantle cell lymphoma: an institutional experience","volume":"13","author":"Mishra","year":"2021","journal-title":"Cureus"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.87","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis","volume":"8","author":"O'Reilly","year":"2024","journal-title":"Hemasphere"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.10.009","article-title":"SOHO state of the art updates and next questions | The current state of CAR T-cell therapy and bispecific antibodies in mantle cell lymphoma","volume":"25","author":"Weiss","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020291","article-title":"Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy","volume":"13","author":"Marangon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4132\/jptm.2024.01.04","article-title":"Clinicopathological implications of immunohistochemical expression of TBX21, CXCR3, GATA3, CCR4, and TCF1 in nodal follicular helper T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified","volume":"58","author":"Han","year":"2024","journal-title":"J Pathol Transl Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/hon.2846","article-title":"What's new in peripheral T-cell lymphomas","volume":"39","author":"Luminari","year":"2021","journal-title":"Hematol Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282025","article-title":"DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome","volume":"108","author":"Savage","year":"2023","journal-title":"Haematologica"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092332","article-title":"Peripheral T-cell lymphomas: therapeutic approaches","volume":"14","author":"Sibon","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6478467","article-title":"Breast implant-associated anaplastic large cell lymphoma: A case report and review of the literature","volume":"2017","author":"Ezekwudo","year":"2017","journal-title":"Case Rep Oncol Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1627175\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T12:20:34Z","timestamp":1757074834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1627175\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":85,"alternative-id":["10.3389\/fonc.2025.1627175"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1627175","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"1627175"}}